S&P 500   3,997.87 (-0.12%)
DOW   32,526.17 (-0.11%)
QQQ   309.95 (-0.13%)
AAPL   158.85 (-0.27%)
MSFT   273.51 (-0.10%)
META   201.30 (-0.43%)
GOOGL   103.40 (-1.45%)
AMZN   100.20 (-0.41%)
TSLA   199.07 (+0.75%)
NVDA   263.37 (+0.53%)
NIO   9.54 (+2.91%)
BABA   84.65 (+1.14%)
AMD   95.50 (-0.45%)
T   18.55 (+0.05%)
F   11.73 (+0.09%)
MU   58.53 (-0.17%)
CGC   1.98 (+0.51%)
GE   92.11 (-0.08%)
DIS   97.18 (+0.66%)
AMC   4.74 (+7.48%)
PFE   40.62 (-0.10%)
PYPL   76.69 (-0.04%)
NFLX   305.50 (-0.09%)
S&P 500   3,997.87 (-0.12%)
DOW   32,526.17 (-0.11%)
QQQ   309.95 (-0.13%)
AAPL   158.85 (-0.27%)
MSFT   273.51 (-0.10%)
META   201.30 (-0.43%)
GOOGL   103.40 (-1.45%)
AMZN   100.20 (-0.41%)
TSLA   199.07 (+0.75%)
NVDA   263.37 (+0.53%)
NIO   9.54 (+2.91%)
BABA   84.65 (+1.14%)
AMD   95.50 (-0.45%)
T   18.55 (+0.05%)
F   11.73 (+0.09%)
MU   58.53 (-0.17%)
CGC   1.98 (+0.51%)
GE   92.11 (-0.08%)
DIS   97.18 (+0.66%)
AMC   4.74 (+7.48%)
PFE   40.62 (-0.10%)
PYPL   76.69 (-0.04%)
NFLX   305.50 (-0.09%)
S&P 500   3,997.87 (-0.12%)
DOW   32,526.17 (-0.11%)
QQQ   309.95 (-0.13%)
AAPL   158.85 (-0.27%)
MSFT   273.51 (-0.10%)
META   201.30 (-0.43%)
GOOGL   103.40 (-1.45%)
AMZN   100.20 (-0.41%)
TSLA   199.07 (+0.75%)
NVDA   263.37 (+0.53%)
NIO   9.54 (+2.91%)
BABA   84.65 (+1.14%)
AMD   95.50 (-0.45%)
T   18.55 (+0.05%)
F   11.73 (+0.09%)
MU   58.53 (-0.17%)
CGC   1.98 (+0.51%)
GE   92.11 (-0.08%)
DIS   97.18 (+0.66%)
AMC   4.74 (+7.48%)
PFE   40.62 (-0.10%)
PYPL   76.69 (-0.04%)
NFLX   305.50 (-0.09%)
S&P 500   3,997.87 (-0.12%)
DOW   32,526.17 (-0.11%)
QQQ   309.95 (-0.13%)
AAPL   158.85 (-0.27%)
MSFT   273.51 (-0.10%)
META   201.30 (-0.43%)
GOOGL   103.40 (-1.45%)
AMZN   100.20 (-0.41%)
TSLA   199.07 (+0.75%)
NVDA   263.37 (+0.53%)
NIO   9.54 (+2.91%)
BABA   84.65 (+1.14%)
AMD   95.50 (-0.45%)
T   18.55 (+0.05%)
F   11.73 (+0.09%)
MU   58.53 (-0.17%)
CGC   1.98 (+0.51%)
GE   92.11 (-0.08%)
DIS   97.18 (+0.66%)
AMC   4.74 (+7.48%)
PFE   40.62 (-0.10%)
PYPL   76.69 (-0.04%)
NFLX   305.50 (-0.09%)
OTCMKTS:ABSCF

AB Science - ABSCF Stock Forecast, Price & News

$9.00
0.00 (0.00%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.00
▼
$9.00
50-Day Range
$9.00
▼
$9.00
52-Week Range
$7.25
▼
$13.95
Volume
N/A
Average Volume
400 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABSCF stock logo

About AB Science (OTCMKTS:ABSCF) Stock

AB Science SA operates as a pharmaceutical company. The firm specializes in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Its pipeline includes Masitinib and AB8939. The company was founded by Alain Moussy and Jean-Pierre Kinet on July 11, 2001 and is headquartered in Paris, France.

Receive ABSCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter.

ABSCF Stock News Headlines

March 15, 2023 | finance.yahoo.com
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
March 13, 2023 | finance.yahoo.com
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
March 22, 2023 | PressReach (Ad)
This Stock Has Room To Run
Analysts believe this stock's product demand could rise quickly in the next few years.
February 28, 2023 | finance.yahoo.com
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
January 31, 2023 | finance.yahoo.com
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
December 29, 2022 | finance.yahoo.com
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
December 27, 2022 | finance.yahoo.com
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
December 22, 2022 | finance.yahoo.com
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
March 22, 2023 | PressReach (Ad)
This Stock Has Room To Run
Analysts believe this stock's product demand could rise quickly in the next few years.
December 13, 2022 | marketwatch.com
AB Science Gets Canada Request for Additional Information for Masitinib New Drug Submission
December 13, 2022 | finance.yahoo.com
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
November 21, 2022 | finance.yahoo.com
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
October 10, 2022 | finance.yahoo.com
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
September 30, 2022 | finance.yahoo.com
AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
September 14, 2022 | finance.yahoo.com
AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
September 11, 2022 | reuters.com
AB Science SA
August 25, 2022 | seekingalpha.com
AB Science's ALS drug Alsitek gets EMA review
August 24, 2022 | finance.yahoo.com
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
June 26, 2022 | msn.com
Corpus Christi Museum of Science and History hosts STEM day for kids
June 7, 2022 | finance.yahoo.com
AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy
May 26, 2022 | finance.yahoo.com
AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS
April 29, 2022 | finance.yahoo.com
AB Science reports its revenues for the year 2021 and provides an update on its activities
April 28, 2022 | finance.yahoo.com
AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
February 28, 2022 | finance.yahoo.com
AB Science announces the financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants
February 24, 2022 | finance.yahoo.com
AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications
February 22, 2022 | finance.yahoo.com
AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
February 21, 2022 | finance.yahoo.com
AB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy
See More Headlines
Receive ABSCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AB Science and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ABSCF
CUSIP
N/A
CIK
N/A
Web
www.ab-science.com
Phone
(314) 720-0014
Fax
N/A
Employees
96
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Alain Moussy
    Chairman & Chief Executive Officer
  • Laurent Guy
    Chief Financial Officer
  • Christian Fassotte
    Global Chief Medical Officer
  • Véronique Gélébart
    Head-Clinical Operations & Clinical Development
  • Alexis Bernard
    Head-Veterinary Sales

Key Competitors

View All Competitors













ABSCF Stock - Frequently Asked Questions

How have ABSCF shares performed in 2023?

AB Science's stock was trading at $9.00 at the beginning of the year. Since then, ABSCF shares have increased by 0.0% and is now trading at $9.00.
View the best growth stocks for 2023 here.

What is AB Science's stock symbol?

AB Science trades on the OTCMKTS under the ticker symbol "ABSCF."

How do I buy shares of AB Science?

Shares of ABSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AB Science's stock price today?

One share of ABSCF stock can currently be purchased for approximately $9.00.

How can I contact AB Science?

AB Science's mailing address is 3, Avenue George V, Paris, Ile-de-France 75008. The official website for the company is www.ab-science.com. The company can be reached via phone at (314) 720-0014.

This page (OTCMKTS:ABSCF) was last updated on 3/22/2023 by MarketBeat.com Staff